A

Atreca Inc
OTC:BCEL

Watchlist Manager
Atreca Inc
OTC:BCEL
Watchlist
Price: 0.09 USD 4.65% Market Closed
Market Cap: 3.6m USD

Operating Margin
Atreca Inc

0%
Current
0%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-78.4m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Atreca Inc
F:0C1
1.7m EUR N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
406.5B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
28%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
No Stocks Found

Atreca Inc
Glance View

Market Cap
3.6m USD
Industry
Biotechnology

Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.

BCEL Intrinsic Value
Not Available
A
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-78.4m
/
Revenue
0
What is the Operating Margin of Atreca Inc?

Based on Atreca Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top